Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19

Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveil...

ver descrição completa

Detalhes bibliográficos
Autores: Ortega, Natalia, Ribes, Marta, Vidal, Marta, Rubio, Rocío, Aguilar, Ruth, Williams, Sarah, Barrios, Diana, Alonso, Selena, Hernández-Luis, Pablo, Mitchell, Robert A., Jairoce, Chenjerai, Cruz, Angeline, Jiménez, Alfons, Santano, Rebeca, Méndez, Susana, Lamoglia Puig, Montserrat, Rosell, Neus, Llupià García, Anna, Puyol, Laura, Chi, Jordi, Rodrigo-Melero, Natalia, Parras, Daniel, Serra, Pau, Pradenas Saavedra, Edwards, Trinité, Benjamin, Blanco, Julià, Mayor Aparicio, Alfredo Gabriel, Barroso, Sonia, Varela, Pilar, Vilella, Anna, Trilla Garcia, Antonio De Padua, Santamaria, Pere, Carolis, Carlo, Tortajada, Marta, Izquierdo Lázaro, Luis, Angulo Aguado, Ana, Engel Rocamora, Pablo, Garcia-Basteiro, Alberto L, Moncunill Piñas, Gemma, Dobaño, Carlota, 1969-
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/225440
Acesso em linha:https://hdl.handle.net/2445/225440
Access Level:acceso abierto
Palavra-chave:SARS-CoV-2
Pandèmia de COVID-19, 2020-2023
COVID-19 Pandemic, 2020- 2023
id ES_fea9028c5cc57c8384862f6dca0adc2b
oai_identifier_str oai:recercat.cat:2445/225440
network_acronym_str ES
network_name_str España
repository_id_str
spelling Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19Ortega, NataliaRibes, MartaVidal, MartaRubio, RocíoAguilar, RuthWilliams, SarahBarrios, DianaAlonso, SelenaHernández-Luis, PabloMitchell, Robert A.Jairoce, ChenjeraiCruz, AngelineJiménez, AlfonsSantano, RebecaMéndez, SusanaLamoglia Puig, MontserratRosell, NeusLlupià García, AnnaPuyol, LauraChi, JordiRodrigo-Melero, NataliaParras, DanielSerra, PauPradenas Saavedra, EdwardsTrinité, BenjaminBlanco, JuliàMayor Aparicio, Alfredo GabrielBarroso, SoniaVarela, PilarVilella, AnnaTrilla Garcia, Antonio De PaduaSantamaria, PereCarolis, CarloTortajada, MartaIzquierdo Lázaro, LuisAngulo Aguado, AnaEngel Rocamora, PabloGarcia-Basteiro, Alberto LMoncunill Piñas, GemmaDobaño, Carlota, 1969-SARS-CoV-2Pandèmia de COVID-19, 2020-2023SARS-CoV-2COVID-19 Pandemic, 2020- 2023Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.Nature Publishing Group2026202620212026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion10 p.application/pdfhttps://hdl.handle.net/2445/225440Articles publicats en revistes (Medicina)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1038/s41467-021-24979-9Nature Communications, 2021, vol. 12, num.1https://doi.org/10.1038/s41467-021-24979-9cc-by (c) Ortega, N. et al., 2021http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2254402026-05-29T05:05:01Z
dc.title.none.fl_str_mv Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19
title Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19
spellingShingle Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19
Ortega, Natalia
SARS-CoV-2
Pandèmia de COVID-19, 2020-2023
SARS-CoV-2
COVID-19 Pandemic, 2020- 2023
title_short Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19
title_full Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19
title_fullStr Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19
title_full_unstemmed Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19
title_sort Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19
dc.creator.none.fl_str_mv Ortega, Natalia
Ribes, Marta
Vidal, Marta
Rubio, Rocío
Aguilar, Ruth
Williams, Sarah
Barrios, Diana
Alonso, Selena
Hernández-Luis, Pablo
Mitchell, Robert A.
Jairoce, Chenjerai
Cruz, Angeline
Jiménez, Alfons
Santano, Rebeca
Méndez, Susana
Lamoglia Puig, Montserrat
Rosell, Neus
Llupià García, Anna
Puyol, Laura
Chi, Jordi
Rodrigo-Melero, Natalia
Parras, Daniel
Serra, Pau
Pradenas Saavedra, Edwards
Trinité, Benjamin
Blanco, Julià
Mayor Aparicio, Alfredo Gabriel
Barroso, Sonia
Varela, Pilar
Vilella, Anna
Trilla Garcia, Antonio De Padua
Santamaria, Pere
Carolis, Carlo
Tortajada, Marta
Izquierdo Lázaro, Luis
Angulo Aguado, Ana
Engel Rocamora, Pablo
Garcia-Basteiro, Alberto L
Moncunill Piñas, Gemma
Dobaño, Carlota, 1969-
author Ortega, Natalia
author_facet Ortega, Natalia
Ribes, Marta
Vidal, Marta
Rubio, Rocío
Aguilar, Ruth
Williams, Sarah
Barrios, Diana
Alonso, Selena
Hernández-Luis, Pablo
Mitchell, Robert A.
Jairoce, Chenjerai
Cruz, Angeline
Jiménez, Alfons
Santano, Rebeca
Méndez, Susana
Lamoglia Puig, Montserrat
Rosell, Neus
Llupià García, Anna
Puyol, Laura
Chi, Jordi
Rodrigo-Melero, Natalia
Parras, Daniel
Serra, Pau
Pradenas Saavedra, Edwards
Trinité, Benjamin
Blanco, Julià
Mayor Aparicio, Alfredo Gabriel
Barroso, Sonia
Varela, Pilar
Vilella, Anna
Trilla Garcia, Antonio De Padua
Santamaria, Pere
Carolis, Carlo
Tortajada, Marta
Izquierdo Lázaro, Luis
Angulo Aguado, Ana
Engel Rocamora, Pablo
Garcia-Basteiro, Alberto L
Moncunill Piñas, Gemma
Dobaño, Carlota, 1969-
author_role author
author2 Ribes, Marta
Vidal, Marta
Rubio, Rocío
Aguilar, Ruth
Williams, Sarah
Barrios, Diana
Alonso, Selena
Hernández-Luis, Pablo
Mitchell, Robert A.
Jairoce, Chenjerai
Cruz, Angeline
Jiménez, Alfons
Santano, Rebeca
Méndez, Susana
Lamoglia Puig, Montserrat
Rosell, Neus
Llupià García, Anna
Puyol, Laura
Chi, Jordi
Rodrigo-Melero, Natalia
Parras, Daniel
Serra, Pau
Pradenas Saavedra, Edwards
Trinité, Benjamin
Blanco, Julià
Mayor Aparicio, Alfredo Gabriel
Barroso, Sonia
Varela, Pilar
Vilella, Anna
Trilla Garcia, Antonio De Padua
Santamaria, Pere
Carolis, Carlo
Tortajada, Marta
Izquierdo Lázaro, Luis
Angulo Aguado, Ana
Engel Rocamora, Pablo
Garcia-Basteiro, Alberto L
Moncunill Piñas, Gemma
Dobaño, Carlota, 1969-
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv SARS-CoV-2
Pandèmia de COVID-19, 2020-2023
SARS-CoV-2
COVID-19 Pandemic, 2020- 2023
topic SARS-CoV-2
Pandèmia de COVID-19, 2020-2023
SARS-CoV-2
COVID-19 Pandemic, 2020- 2023
description Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.
publishDate 2021
dc.date.none.fl_str_mv 2021
2026
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/225440
url https://hdl.handle.net/2445/225440
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1038/s41467-021-24979-9
Nature Communications, 2021, vol. 12, num.1
https://doi.org/10.1038/s41467-021-24979-9
dc.rights.none.fl_str_mv cc-by (c) Ortega, N. et al., 2021
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Ortega, N. et al., 2021
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 10 p.
application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425704773353472
score 15,812455